Immunoglobulin Or Antibody Binds A Specifically Identified Amino Acid Sequence Patents (Class 435/331)
  • Patent number: 10457712
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: October 29, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Patent number: 10395341
    Abstract: The present disclosure provides a panoramic image generation method and apparatus for a user terminal. The panoramic image generation method for a user terminal includes: obtaining a plurality of images shot by a user terminal, determining an adjacence relationship among the plurality of images, and performing feature matching on adjacent images to obtain matched feature-point-pairs; obtaining an optimized camera parameter according to the matched feature-point-pairs and an initial camera parameter; performing a color adjustment on the adjacent images to obtain color adjusted adjacent images; and mosaicking the color adjusted adjacent images according to the optimized camera parameter to generate a panoramic image.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 27, 2019
    Assignee: BAIDU ONLINE NETWORK TECHNOLOGY (BEIJING) CO., LTD.
    Inventors: Guofu Xie, Rui Al, Li Liu, Wenbo Hou, Xianpeng Lang
  • Patent number: 10336811
    Abstract: The disclosure relates to a recombinant membrane span protein complex, comprising (1) a fusion protein, comprising a membrane span protein fused to a kinase domain, preferably a constitutive kinase and (2) a reporter construct comprising a polypeptide, interacting with the membrane span protein, fused to a reporter phosphorylation domain. The disclosure relates further to the uses of such membrane span protein complex for the detection of compounds that interact with the membrane span protein and for the screening and/or detection of inhibitors of the compound-membrane span protein interactions. In a preferred embodiment, the membrane span protein is a G protein coupled receptor (GPCR) and the method is used for the screening and/or detection of inhibitors of the ligand-receptor binding.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: July 2, 2019
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Samuel Lievens
  • Patent number: 10295547
    Abstract: Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 21, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Laura Ranum, Tao Zu
  • Patent number: 10294478
    Abstract: The present invention relates to a nucleic acid aptamer molecule that includes a domain that binds to an estrogen receptor, molecular complexes that include the nucleic acid aptamer molecule and an estrogen receptor, and constructed DMA molecules and expression systems, as well as host cells, that the contain an RNA aptamer molecule of the invention. Use of these aptamers and encoding constructs to inhibiting estrogen receptor activity in a cell and to treat estrogen receptor-positive cancers is also described.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: May 21, 2019
    Assignee: The Research Foundation for The State University of New York
    Inventors: Hua Shi, Daiying Xu, Vamsee Krishna Chatakonda
  • Patent number: 10222387
    Abstract: The present invention relates to a method of identifying a compound that binds to or modulates the activity of one or more polypeptides encoding one or more receptors that are involved in the detection and perception of fatty acids.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: March 5, 2019
    Assignee: MARS, INCORPORATED
    Inventors: Scott Joseph McGrane, Andrew John Taylor, Matthew Ronald Gibbs, Richard Masten Fine, Boris Klebansky
  • Patent number: 10179111
    Abstract: Methods for inhibiting tissue ossification or calcification in a subject, comprising administering a therapeutically effective amount of BMP I inhibitor-loaded microparticles to a subject in need thereof, wherein the administration provides local and sustained release of the BMP I inhibitor thereby inhibiting tissue ossification or calcification.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: January 15, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Riccardo Gottardi, Peter Alexander, Patrick A. Bianconi, Steven R. Little
  • Patent number: 9994633
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 12, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
  • Patent number: 9945873
    Abstract: The present invention relates to methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient. More particularly, the present invention relates to a method for predicting the risk of having an organ failure selected from the group consisting of respiratory failure, renal failure and thrombopenia in a septic patient comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said septic patient.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: April 17, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE DROIT ET DE LA SANTE LILLE 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventor: Philippe Lassalle
  • Patent number: 9718864
    Abstract: The present invention pertains to fields of biochemistry and molecular biology, relates to an ?O-superfamily conotoxin peptide, pharmaceutical composition thereof, preparation method and use thereof. The present invention further relates to a propeptide of the conotoxin peptide, nucleic acid construct thereof, expression vector and transformed cell thereof, and fusion protein thereof. The present invention further relates to a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The new ?O-superfamily conotoxin peptide of the present invention is capable of specifically blocking acetylcholine receptor (nAChRs) (e.g., ?9?10 nAChR), and NMDA receptor (e.g.
    Type: Grant
    Filed: June 8, 2013
    Date of Patent: August 1, 2017
    Assignee: HAINAN UNIVERSITY
    Inventors: Sulan Luo, Dongting Zhangsun, Yong Wu, Xiaopeng Zhu, Yuanyan Hu, J. Michael McIntosh
  • Patent number: 9657060
    Abstract: The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: May 23, 2017
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Michael C. Carroll, Francis D. Moore, Herbert B. Hechtman
  • Patent number: 9127072
    Abstract: The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: September 8, 2015
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Jun Xu, Charles Esmon
  • Publication number: 20150147333
    Abstract: Provided herein are anti-RSPO antibodies, in particular anti-RSPO2 antibodies and/or anti-RSPO3 antibodies, and methods of using the same.
    Type: Application
    Filed: October 17, 2014
    Publication date: May 28, 2015
    Applicant: GENENTECH, INC.
    Inventors: Elaine Storm, Frederic J. de Sauvage, Jeremy M. Murray, Cameron L. Noland, Yan Wu, Christine Tan, Jo-Anne Hongo, Yongmei Chen
  • Publication number: 20150147763
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 28, 2015
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll
  • Publication number: 20150140000
    Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Inventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot
  • Publication number: 20150141274
    Abstract: Disclosed herein are methods, compositions, and kits for isolating actively translated mRNA from heterogeneous cell populations. Also disclosed herein are methods, compositions, and kits for identifying cell types that respond to stimuli in heterogeneous cell populations.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 21, 2015
    Inventors: Jeffrey M. Friedman, Zachary A. Knight, Keith Tan, Kivan Birsoy
  • Publication number: 20150140001
    Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clecl4a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clecl4a as an epitope for an antibody suppressive of angiogenesis.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Applicant: SCRIPPS KOREA ANTIBODY INSTITUTE
    Inventors: Suk Mook Lee, Min kyoung Ki, Mee Hyun Jeoung, Jong Rip Choi
  • Patent number: 9034643
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 19, 2015
    Assignee: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Publication number: 20150132311
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Inventors: Robert Arch, Jun Zhang, Michelle Madar, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
  • Publication number: 20150132218
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 20, 2014
    Publication date: May 14, 2015
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Publication number: 20150132288
    Abstract: The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: September 13, 2012
    Publication date: May 14, 2015
    Applicant: BiocerOX Products B.V.
    Inventors: Petrus Johannes Simons, Louis Boon
  • Publication number: 20150132303
    Abstract: A monoclonal antibody against oncostatin M specific receptor beta subunit, a hybridoma capable of producing the same and a medicament for treating atopic dermatitis comprising the same.
    Type: Application
    Filed: May 10, 2013
    Publication date: May 14, 2015
    Inventors: Yoshihiro Morikawa, Tadasuke Komori, Eiji Esashi, Ayumi Kotaki
  • Publication number: 20150125455
    Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 7, 2015
    Inventors: Larry L. GREEN, Qing ZHOU, Bruce A. KEYT, Xiao-Dong YANG, Stephen Charles EMERY, David Charles BLAKEY
  • Publication number: 20150126713
    Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases such as ophthalmic disease, inflammatory bowel disease, or psoriasis in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:10 or 14 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:6 or 18.
    Type: Application
    Filed: February 27, 2013
    Publication date: May 7, 2015
    Applicant: Astellas Pharma Inc.
    Inventors: Atsuo Yonezawa, Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi
  • Publication number: 20150125885
    Abstract: The present invention relates to a RTN4B-related polypeptide, a monoclonal antibody thereof, a monoclonal antibody-producing hybridoma cell strain, and, preparation and applications thereof The RTN4B polypeptide comprises an amino acid sequence presented by SEQ ID NO: 1. The invention further discloses a monoclonal antibody, a hybridoma cell strain to produce the monoclonal antibody prepared by the RTN4B polypeptide, and the related application in the treatment or prevention of tumors thereof.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 7, 2015
    Inventors: Long Yu, Guoqing Ji, Dingding Han, Yanhua Wu, Lisha Tang
  • Publication number: 20150125460
    Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Susan L. Kalled, Yen-Ming Hsu
  • Publication number: 20150125454
    Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.
    Type: Application
    Filed: April 9, 2013
    Publication date: May 7, 2015
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
  • Publication number: 20150125458
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Publication number: 20150125456
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Application
    Filed: October 22, 2014
    Publication date: May 7, 2015
    Applicant: CELERA CORPORATION
    Inventors: Yeounjin KIM, Tao HE, Steve RUBEN
  • Publication number: 20150118241
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists.
    Type: Application
    Filed: May 14, 2013
    Publication date: April 30, 2015
    Inventors: Sha Mi, R. Blake Pepinsky
  • Publication number: 20150118237
    Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 30, 2015
    Inventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
  • Publication number: 20150118240
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 30, 2015
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Publication number: 20150118184
    Abstract: A monoclonal antibody recognizing the extracellular region of LAMP5 was produced. The produced antibody demonstrated antibody-dependent cell-mediated cytotoxic activity, and/or cell growth inhibitory activity in the presence of a toxin-labeled secondary antibody, against a multiple myeloma cell line.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 30, 2015
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventor: Shigeto Kawai
  • Publication number: 20150110781
    Abstract: The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection.
    Type: Application
    Filed: May 24, 2012
    Publication date: April 23, 2015
    Inventors: Enyun Shen, Shiqi Ren
  • Publication number: 20150110794
    Abstract: This disclosure provides anti-human cytomegalovirus antibodies and methods of treatment, prophylaxis, detection, and diagnosis using the same. In another aspect, the disclosure features therapeutic, prophylactic, and/or diagnostic compositions for human cytomegalovirus infection or for a human cytomegalovirus-related disease that include a binding agent (e.g., antibody) or polynucleotide disclosed herein. In some embodiments, the composition is formulated for ocular or topical administration. The compositions can further include one or more human cytomegalovirus-neutralizing antibodies, an intravenous immunoglobulin preparation, and/or one or more antiviral compounds (e.g., ganciclovir, foscamet, cidofovir, or valganciclovir).
    Type: Application
    Filed: April 30, 2013
    Publication date: April 23, 2015
    Inventors: Shuji Sato, Sean Andre Beausoleil, Wan Cheung Cheung, Roberto D. Polakiewicz
  • Publication number: 20150110793
    Abstract: The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human Epiregulin-expressing cancer cells.
    Type: Application
    Filed: December 28, 2012
    Publication date: April 23, 2015
    Inventors: Hirotake Shiraiwa, Keiko Esaki, Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Shigero Tamba, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Yasuko Kinoshita, Masami Suzuki, Atsuhiko Kato, Etsuko Takeiri, Eri Hashimoto, Yoshinori Watanabe
  • Publication number: 20150110777
    Abstract: The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Application
    Filed: July 11, 2014
    Publication date: April 23, 2015
    Inventors: Robin Barbour, Yue Liu
  • Publication number: 20150110791
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: May 20, 2014
    Publication date: April 23, 2015
    Applicant: GENENTECH, INC.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • Publication number: 20150111251
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: September 25, 2014
    Publication date: April 23, 2015
    Inventors: Chung-ming HSIEH, Carrie GOODREAU, Tariq GHAYUR, Achim MOELLER, Sahana BOSE
  • Publication number: 20150110792
    Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Application
    Filed: November 16, 2012
    Publication date: April 23, 2015
    Inventors: Veronique Bailly, Ellen Garber, Paul D. Rennert, Nicholas Joseph Lennemann, Wendy Jean Maury, Sven Henrik Moller-Tank
  • Publication number: 20150111197
    Abstract: The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.
    Type: Application
    Filed: July 18, 2014
    Publication date: April 23, 2015
    Applicant: INSTITUT PASTEUR
    Inventors: PHILIPPE DESPRES, ANNE-CLAIRE BREHIN, VALERIE MARECHAL, PIERRE CHARNEAU, PHILIPPE SOUQUE
  • Publication number: 20150104409
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: October 20, 2014
    Publication date: April 16, 2015
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Publication number: 20150104457
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Application
    Filed: June 25, 2013
    Publication date: April 16, 2015
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Publication number: 20150104866
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David B. PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU
  • Patent number: 9005921
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: April 14, 2015
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Publication number: 20150098947
    Abstract: Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 9, 2015
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philippe HAMMEL
  • Publication number: 20150098900
    Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 24, 2014
    Publication date: April 9, 2015
    Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
  • Publication number: 20150098945
    Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenic effects in in-vivo models.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 9, 2015
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
  • Publication number: 20150098946
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 9, 2015
    Applicant: Genentech, Inc.
    Inventors: Sunil Bhakta, Meredith Hazen, Jo-Anne S Hongo, Jagath R Junutula, Isidro Hotzel, Yonglei Shang, Shang-Fan Yu
  • Patent number: 8993731
    Abstract: A humanized agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: March 31, 2015
    Assignee: UCB Biopharma SPRL
    Inventor: Kerry Louise Tyson